Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Blood (2023) 142 (Supplement 1): 380.

https://doi.org/10.1182/blood-2023-189505

Published: 2023

Journal Articles

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Charalambos Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Susan M. Geyer, Patrick J. Stiff, Brian T. Hill, Mitchell Horwitz, Farhad Khimani, Richard F. Little, Shira N. Dinner, Jonathan W. Friedberg, Brad S. Kahl, Miguel-Angel Perales, Steven M. Devine, John P. Leonard, Nancy L. Bartlett

Blood (2023) 142 (Supplement 1): 437.

https://doi.org/10.1182/blood-2023-173742

Published: 2023

Journal Articles

Distribution of Chromosome-Arm Specific Telomere Length in Patients with Telomere Biology Disorders

Alejandro Ferrer, Zachary D Stephens, Susan M. Geyer, Rachel A Simon, Terra L Lasho, Christy M Finke, Brittany Burnap, Lindsay A Mulvihill, Tammy M McAllister, Carolyn R. Rohrer Vitek, Konstantinos N Lazaridis, Angita Jain, Eric W Klee, Jean-Pierre A Kocher, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4103.

https://doi.org/10.1182/blood-2023-187486

Published: 2023

Journal Articles

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

N. Nora Bennani, Joselle Cook, Susan M. Geyer, Brenda F Ginos, Lianwen Zhang, Javier Munoz, Stephen Broski, Stephen Russell, Kah-Whye Peng, Martha Lacy

Blood (2023) 142 (Supplement 1): 5004.

https://doi.org/10.1182/blood-2023-190664

Published: 2023

Journal Articles

Outcomes in Mantle Cell Lymphoma with Central Nervous System Involvement - a Dual Center Study

Blood (2023) 142 (Supplement 1): 1670.

https://doi.org/10.1182/blood-2023-174701

Published: 2023

Journal Articles

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

Blood (2023) 142 (Supplement 1): 182.

https://doi.org/10.1182/blood-2023-179573

Published: 2023

Journal Articles

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood (2022) 140 (Supplement 1): 2887–2890.

https://doi.org/10.1182/blood-2022-162367

Published: 2022

Journal Articles

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

Blood (2022) 140 (Supplement 1): 3543–3545.

https://doi.org/10.1182/blood-2022-157051

Published: 2022

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project

Marissa Li, Terra Lasho, Moritz Binder, Wazim Mohammed Ismail, Susan M. Geyer, Jenna Fernandez, Yael Kusne, Abhishek A. Mangaonkar, Minsuk Kim, Alexandre Gaspar Maia, Nicholas Chia, Mrinal M. Patnaik

Blood (2021) 138 (Supplement 1): 2164.

https://doi.org/10.1182/blood-2021-151548

Published: 2021

Journal Articles

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)

Elizabeth K. O'Donnell, Vera Jean Suman, Susan M. Geyer, Omar Nadeem, Shira Dinner, Andrew J. Yee, Jacob P. Laubach, Clifton C. Mo, Sascha A. Tuchman, Kristen Donadio, Sarah Sinclair, Noopur S. Raje, Paul G. Richardson

Blood (2021) 138 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2021-146274

Published: 2021

Journal Articles

An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS)

Blood (2021) 138 (Supplement 1): 1333.

https://doi.org/10.1182/blood-2021-153184

Published: 2021

Journal Articles

Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias

Ahmad Nanaa, Rama Nana, Zhuoer Xie, MD, Dragan Jevremovic, MD PhD, Phuong L. Nguyen, MD, Cynthia Hengel, Susan M. Geyer, PhD, Rong He, MD, David S. Viswanatha, MD, Michael M. Timm, Mohamed E Salama, MD, Min Shi, MDPhD, Patricia Greipp, DO, Hassan B. Alkhateeb, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Mrinal M. Patnaik, MDMBBS, Mithun Vinod Shah, MD PhD, Aref Al-Kali, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142181

Published: 2020

Journal Articles

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Blood (2018) 132 (Supplement 1): 2668.

https://doi.org/10.1182/blood-2018-99-114318

Published: 2018

Journal Articles

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

Blood (2017) 130 (Supplement 1): 467.

https://doi.org/10.1182/blood.V130.Suppl_1.467.467

Published: 2017

Journal Articles

Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype

David A Sallman, MD, McLemore Amy, Rami S. Komrokji, MD, Kathy McGraw, PhD, Susan M. Geyer, PhD, Erika Eksioglu, PhD MS, Najla Al Ali, M.Sc, Jeffrey E. Lancet, MD, Sheng Wei, MD, Eric Padron, MD, Alan F. List, MD

Blood (2017) 130 (Supplement 1): 423.

https://doi.org/10.1182/blood.V130.Suppl_1.423.423

Published: 2017

Journal Articles

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Blood (2017) 130 (Supplement 1): 2580.

https://doi.org/10.1182/blood.V130.Suppl_1.2580.2580

Published: 2017

Journal Articles

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Blood (2017) 130 (Supplement 1): 145.

https://doi.org/10.1182/blood.V130.Suppl_1.145.145

Published: 2017

Journal Articles

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

Farrukh T. Awan, Neil E. Kay, Melanie E. Davis, Wenting Wu, Susan M. Geyer, Nelson Leung, Diane F. Jelinek, Renee C. Tschumper, Charla R. Secreto, Thomas S. Lin, Michael R. Grever, Tait D. Shanafelt, Clive S. Zent, Timothy G. Call, Nyla A. Heerema, Gerard Lozanski, John C. Byrd, David M. Lucas

Blood (2009) 113 (3): 535–537.

https://doi.org/10.1182/blood-2008-08-173450

Published: 2009

Journal Articles

Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era

Thomas M. Habermann, Sophia S. Wang, Matthew J. Maurer, Lindsay M. Morton, Charles F. Lynch, Stephen M. Ansell, Patricia Hartge, Richard K. Severson, Nathaniel Rothman, Scott Davis, Susan M. Geyer, Wendy Cozen, Stephen J. Chanock, James R. Cerhan

Blood (2008) 112 (7): 2694–2702.

https://doi.org/10.1182/blood-2007-09-111658

Published: 2008

Includes: Supplemental data

Journal Articles

Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).

Clive S. Zent, MD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Diane F. Jelinek, PhD, Renee C. Tschumper, Charla R. Secreto, Deborah A. Bowen, RN, Susan M. Geyer, PhD, Brian F. Kabat, Betsy R. LaPlant, Wenting Wu, PhD, Neil E. Kay, MR

Blood (2007) 110 (11): 2050.

https://doi.org/10.1182/blood.V110.11.2050.2050

Published: 2007

NARROW

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Distribution of Chromosome-Arm Specific Telomere Length in Patients with Telomere Biology Disorders

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

Outcomes in Mantle Cell Lymphoma with Central Nervous System Involvement - a Dual Center Study

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)

An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS)

Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era

Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only